Researchers have identified a previously overlooked layer of Alzheimer's disease operating at the level of DNA architecture itself, not just genetic mutations. The finding reveals that the three-dimensional organization of DNA becomes disrupted in multiple types of brain cells affected by the disease, which disrupts normal gene regulation and expression.
The discovery centers on how DNA folds and organizes within the nucleus. DNA does not sit flat in cells. Instead, it coils and loops into complex three-dimensional structures that determine which genes stay active and which remain silent. This spatial organization, called chromatin architecture, acts as a master control system for genetic function. When this architecture breaks down, genes that should be active become dormant, and vice versa. In Alzheimer's disease, researchers found this disruption occurs across several brain cell types that degenerate in the disease.
The study examined chromatin organization in neurons and glial cells, the support cells that surround neurons. Scientists used advanced imaging and sequencing techniques to map how DNA folds differ in healthy brains compared to Alzheimer's-affected brains. The altered three-dimensional arrangement changed access to genes involved in neuroinflammation, synaptic function, and neurodegeneration. Some genes critical for protecting brain health became less accessible, while others associated with inflammation and cell death became more active.
This finding represents a shift in how researchers think about Alzheimer's genetics. For decades, the field focused primarily on identifying specific gene mutations that increase disease risk. The APOE4 variant remains the strongest genetic risk factor. However, mutations alone do not explain all Alzheimer's cases or their severity. This discovery suggests that how DNA organizes and functions matters equally, if not more, than having specific disease-linked genes.
The implications extend to treatment development. Most current Alzheimer's therapies target protein buildup, such as amyloid plaques and tau tangles. These approaches show modest benefits. A deeper understanding of chromatin dysfunction could reveal new drug targets. If scientists can develop therapies that restore proper DNA organization or compensate for disrupted gene regulation, they might slow or prevent neurodegeneration at an earlier stage than current treatments allow.
The work also highlights why Alzheimer's remains so difficult to treat. The disease operates on multiple levels simultaneously. Genetic risk factors influence disease development. Protein misfolding accelerates neurodegeneration. Now researchers recognize that the spatial organization controlling how genes function fundamentally changes in the disease. Each layer presents both barriers and opportunities for intervention.
Next steps involve identifying which specific DNA organizational changes drive the most damage and whether these changes appear early in the disease process. If chromatin dysfunction precedes protein accumulation, it could serve as an early biomarker for disease detection. Researchers also plan to investigate whether restoring normal chromatin architecture could reverse some neurodegeneration in animal models before testing in humans.
This work expands the biological complexity researchers must consider to develop effective Alzheimer's treatments and explains why single-target therapies have proven insufficient.